<DOC>
	<DOC>NCT00330200</DOC>
	<brief_summary>The aim of this study is to examine the effects of ISIS 113715 monotherapy on insulin sensitivity, glucose and lipid metabolism and energy expenditure in subjects with type 2 diabetes mellitus.</brief_summary>
	<brief_title>Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Male or female (post menopausal and/or surgically sterile) Aged 18 to 70 years Treatment na√Øve subjects with fasting blood glucose levels of 150220 mg/dL, hematocrit of &gt;/= 35% and HbA1c levels of &gt;/= 7% and &lt;/= 10.0% Subjects on antidiabetic therapy with fasting blood glucose levels of 100200 mg/dL, hematocrit of &gt;/= 35%, and HbA1c levels of &gt;/= 6.5% and &lt;/= 9.0% Greater than 3 severe hypoglycemic episodes within six months of screen Pregnant, breastfeeding, or intends to become pregnant Clinical signs or symptoms of liver disease, acute or chronic hepatitis, or ALT greater than 1.5 times the upper limit of normal History of hepatitis B surface antigen, hepatitis C antibody, or HIV Complications of diabetes (e.g., neuropathy, nephropathy, and retinopathy) Clinically significant and currently active diseases Clinically significant abnormalities in medical history, physical examination, or laboratory examination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Fasting plasma glucose</keyword>
	<keyword>HbA1c</keyword>
	<keyword>Metabolism</keyword>
</DOC>